Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Background Despite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival outcomes dependent on the type of first-line ther...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Lucie Heinzerling, Lisa Zimmer, Ralf Gutzmer, Andrea Forschner, Elisabeth Livingstone, Bastian Schilling, Selma Ugurel, Peter Mohr, Thilo Gambichler, Patrick Terheyden, Sebastian Haferkamp, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Carsten Weishaupt, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Maike Trommer, Jürgen Christian Becker, Ulrike Leiter, Cindy Franklin, Christoffer Gebhardt, Katharina Kahler, Leonie Bluhm, Imke Grimmelmann, Marlene Garzarolli, Dorothee Nashan, Michael Sachse, Julia Welzel, Gerhard Weyandt, Susanne Horn, Fabian Ziller, Harald Löffler, Stephan Grabbe, Gaston Schley, Georg Lodde, Jan-Malte Placke, Anca Sindrilaru
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: BMJ Publishing Group 2023-04-01
Sarja:Journal for ImmunoTherapy of Cancer
Linkit:https://jitc.bmj.com/content/11/4/e005828.full

Internet

https://jitc.bmj.com/content/11/4/e005828.full

Samankaltaisia teoksia